Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects must have a PiZZ genotype confirmed at screening~* Plasma AAT levels indicating severe deficiency at screening~Key Exclusion Criteria:~* History of a medical condition that could negatively impact the ability to complete the study~* Solid organ, or hematological transplantation or is currently on a transplant list~* History of use of gene therapy or RNAi therapy at any time previously~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to VX-864 in the treatment period for 28 days.
- VX-864 100 mg (Type: EXPERIMENTAL): Participants received VX-864 100 milligrams (mg) every 12 hours (q12h) in the treatment period for 28 days.
- VX-864 300 mg (Type: EXPERIMENTAL): Participants received VX-864 300 mg q12h in the treatment period for 28 days.
- VX-864 500 mg (Type: EXPERIMENTAL): Participants received VX-864 500 mg q12h in the treatment period for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).